Morgan Stanley resumed coverage of Royalty Pharma (RPRX) with an Overweight rating and $51 price target The firm cites se the company’s diversified portfolio and insulation from potential tariffs, coupled with a growth profile above the peer average, as positives.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue